Regeneron: Data Shows REGN-COV2 Reduced Virus Levels, Need for Further Medical Attention

   By Stephen Nakrosis 
 

Regeneron Pharmaceuticals on Wednesday said positive prospective results from an ongoing Phase 2/3 trial of its REGN-COV2 Antibody Cocktail in Covid-19 patients demonstrated the treatment "significantly reduced virus levels and need for further medical attention."

The company said the recent data, involving 524 patients from the ongoing trial in a Covid-19 outpatient setting, showed REGN-COV2 "met the primary and key secondary endpoints," adding that it "significantly reduced viral load and patient medical visits."

Regeneron said it shared the results with the U.S. Food and Drug Administration, which is "reviewing an Emergency Use Authorization submission for the REGN-COV2 low dose in adults with mild-to-moderate Covid-19 who are at high risk for poor outcomes."

George D. Yancopoulos, president and chief scientific officer of Regeneron, said, "Today's analysis, involving more than 500 additional patients, prospectively confirms that REGN-COV2 can indeed significantly reduce viral load and further shows that these viral reductions are associated with a significant decrease in the need for further medical attention," adding, "We continue to see the strongest effects in patients who are most at risk for poor outcomes due to high viral load, ineffective antibody immune response at baseline, or pre-existing risk factors."

The company said "REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes Covid-19."

--Write to Stephen Nakrosis at [e-mail]

(END) Dow Jones Newswires

October 28, 2020 19:11 ET (23:11 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.